Efficacy of teicoplanin in experimental group B streptococcal bacteremia and meningitis

Kwang Sik Kim, Jane H. Kang, Arnold S. Bayer

Research output: Contribution to journalArticle

Abstract

We evaluated the activity of teicoplanin against a type-ill group B streptococcal strain in vitro and in vivo and compared the results with those of penicillin G. In vitro, the minimal inhibitory and minimal bactericidal concentrations of teicoplanin were 2- to 4-fold greater than those of penicillin G. In vivo studies were carried out with an experimental bacteremia and meningitis model in newborn rats. Eighty-one infected animals were randomized to receive teicoplanin 5, 10 or 20 mg/kg, twice daily, or penicillin G 50 or 200 mg/kg, twice daily, or saline (0.05 ml), twice daily. The mean serum levels of teicoplanin were maintained above 100x the minimal bactericidal concentration for 7-8 h even with a dose of 5 mg/kg. The mean penetration of teicoplanin into the cerebrospinal fluid was estimated as 2.4-8.2% of those of concomitant levels in serum. The overall efficacy of teicoplanin was similar to that of penicillin G as judged by mortality rates. However, two bacteremic animals which were free of meningitis at the beginning of therapy developed this complication during 4 days of teicoplanin therapy, in contrast with none in the penicillin group. Further studies are needed to understand the reason(s) for these failures with teicoplanin therapy.

Original languageEnglish (US)
Pages (from-to)177-182
Number of pages6
JournalChemotherapy
Volume33
Issue number3
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Teicoplanin
Bacteremia
Meningitis
Penicillin G
Serum
Penicillins
Cerebrospinal Fluid
Therapeutics
Mortality

Keywords

  • Bacteremia
  • Group B Streptococci
  • In vitro/in vivo studies
  • Meningitis
  • Penicillin G
  • Teicoplanin

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Cite this

Efficacy of teicoplanin in experimental group B streptococcal bacteremia and meningitis. / Kim, Kwang Sik; Kang, Jane H.; Bayer, Arnold S.

In: Chemotherapy, Vol. 33, No. 3, 1987, p. 177-182.

Research output: Contribution to journalArticle

Kim, Kwang Sik ; Kang, Jane H. ; Bayer, Arnold S. / Efficacy of teicoplanin in experimental group B streptococcal bacteremia and meningitis. In: Chemotherapy. 1987 ; Vol. 33, No. 3. pp. 177-182.
@article{f996d0a017bf49a0b8eaa5245d26325a,
title = "Efficacy of teicoplanin in experimental group B streptococcal bacteremia and meningitis",
abstract = "We evaluated the activity of teicoplanin against a type-ill group B streptococcal strain in vitro and in vivo and compared the results with those of penicillin G. In vitro, the minimal inhibitory and minimal bactericidal concentrations of teicoplanin were 2- to 4-fold greater than those of penicillin G. In vivo studies were carried out with an experimental bacteremia and meningitis model in newborn rats. Eighty-one infected animals were randomized to receive teicoplanin 5, 10 or 20 mg/kg, twice daily, or penicillin G 50 or 200 mg/kg, twice daily, or saline (0.05 ml), twice daily. The mean serum levels of teicoplanin were maintained above 100x the minimal bactericidal concentration for 7-8 h even with a dose of 5 mg/kg. The mean penetration of teicoplanin into the cerebrospinal fluid was estimated as 2.4-8.2{\%} of those of concomitant levels in serum. The overall efficacy of teicoplanin was similar to that of penicillin G as judged by mortality rates. However, two bacteremic animals which were free of meningitis at the beginning of therapy developed this complication during 4 days of teicoplanin therapy, in contrast with none in the penicillin group. Further studies are needed to understand the reason(s) for these failures with teicoplanin therapy.",
keywords = "Bacteremia, Group B Streptococci, In vitro/in vivo studies, Meningitis, Penicillin G, Teicoplanin",
author = "Kim, {Kwang Sik} and Kang, {Jane H.} and Bayer, {Arnold S.}",
year = "1987",
doi = "10.1159/000238492",
language = "English (US)",
volume = "33",
pages = "177--182",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Efficacy of teicoplanin in experimental group B streptococcal bacteremia and meningitis

AU - Kim, Kwang Sik

AU - Kang, Jane H.

AU - Bayer, Arnold S.

PY - 1987

Y1 - 1987

N2 - We evaluated the activity of teicoplanin against a type-ill group B streptococcal strain in vitro and in vivo and compared the results with those of penicillin G. In vitro, the minimal inhibitory and minimal bactericidal concentrations of teicoplanin were 2- to 4-fold greater than those of penicillin G. In vivo studies were carried out with an experimental bacteremia and meningitis model in newborn rats. Eighty-one infected animals were randomized to receive teicoplanin 5, 10 or 20 mg/kg, twice daily, or penicillin G 50 or 200 mg/kg, twice daily, or saline (0.05 ml), twice daily. The mean serum levels of teicoplanin were maintained above 100x the minimal bactericidal concentration for 7-8 h even with a dose of 5 mg/kg. The mean penetration of teicoplanin into the cerebrospinal fluid was estimated as 2.4-8.2% of those of concomitant levels in serum. The overall efficacy of teicoplanin was similar to that of penicillin G as judged by mortality rates. However, two bacteremic animals which were free of meningitis at the beginning of therapy developed this complication during 4 days of teicoplanin therapy, in contrast with none in the penicillin group. Further studies are needed to understand the reason(s) for these failures with teicoplanin therapy.

AB - We evaluated the activity of teicoplanin against a type-ill group B streptococcal strain in vitro and in vivo and compared the results with those of penicillin G. In vitro, the minimal inhibitory and minimal bactericidal concentrations of teicoplanin were 2- to 4-fold greater than those of penicillin G. In vivo studies were carried out with an experimental bacteremia and meningitis model in newborn rats. Eighty-one infected animals were randomized to receive teicoplanin 5, 10 or 20 mg/kg, twice daily, or penicillin G 50 or 200 mg/kg, twice daily, or saline (0.05 ml), twice daily. The mean serum levels of teicoplanin were maintained above 100x the minimal bactericidal concentration for 7-8 h even with a dose of 5 mg/kg. The mean penetration of teicoplanin into the cerebrospinal fluid was estimated as 2.4-8.2% of those of concomitant levels in serum. The overall efficacy of teicoplanin was similar to that of penicillin G as judged by mortality rates. However, two bacteremic animals which were free of meningitis at the beginning of therapy developed this complication during 4 days of teicoplanin therapy, in contrast with none in the penicillin group. Further studies are needed to understand the reason(s) for these failures with teicoplanin therapy.

KW - Bacteremia

KW - Group B Streptococci

KW - In vitro/in vivo studies

KW - Meningitis

KW - Penicillin G

KW - Teicoplanin

UR - http://www.scopus.com/inward/record.url?scp=0023218203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023218203&partnerID=8YFLogxK

U2 - 10.1159/000238492

DO - 10.1159/000238492

M3 - Article

VL - 33

SP - 177

EP - 182

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 3

ER -